- Home
- CERT vs PRCT Comparison
CERT vs PRCT Comparison
Compare CERT & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERT
- PRCT
- Stock Information
- Founded
- CERT 2008
- PRCT 2009
- Country
- CERT United States
- PRCT United States
- Employees
- CERT N/A
- PRCT N/A
- Industry
- CERT Retail: Computer Software & Peripheral Equipment
- PRCT Medical Specialities
- Sector
- CERT Technology
- PRCT Health Care
- Exchange
- CERT Nasdaq
- PRCT Nasdaq
- Market Cap
- CERT 1.9B
- PRCT 1.8B
- IPO Year
- CERT 2020
- PRCT 2021
- Fundamental
- Price
- CERT $12.68
- PRCT $35.34
- Analyst Decision
- CERT Buy
- PRCT Buy
- Analyst Count
- CERT 8
- PRCT 8
- Target Price
- CERT $15.57
- PRCT $67.14
- AVG Volume (30 Days)
- CERT 1.8M
- PRCT 1.1M
- Earning Date
- CERT 11-06-2025
- PRCT 11-04-2025
- Dividend Yield
- CERT N/A
- PRCT N/A
- EPS Growth
- CERT N/A
- PRCT N/A
- EPS
- CERT 0.05
- PRCT N/A
- Revenue
- CERT $405,755,000.00
- PRCT $274,950,000.00
- Revenue This Year
- CERT $11.70
- PRCT $48.38
- Revenue Next Year
- CERT $8.03
- PRCT $30.87
- P/E Ratio
- CERT $255.18
- PRCT N/A
- Revenue Growth
- CERT 11.61
- PRCT 55.71
- 52 Week Low
- CERT $8.64
- PRCT $32.11
- 52 Week High
- CERT $15.69
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- CERT 55.27
- PRCT 50.91
- Support Level
- CERT $12.03
- PRCT $34.32
- Resistance Level
- CERT $12.83
- PRCT $36.69
- Average True Range (ATR)
- CERT 0.57
- PRCT 1.73
- MACD
- CERT -0.05
- PRCT 0.41
- Stochastic Oscillator
- CERT 53.46
- PRCT 82.10
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.